GlassScriptPhysician profile
Janki Patel
NPI 1548606668
$8,195.81
in general payments reported to CMS, 2019-2025
36 companies · $2,164 in 2025
The $2,164 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $311 · 2020: $436 · 2021: $599 · 2022: $1,384 · 2023: $1,536 · 2024: $1,765 · 2025: $2,164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,424 · Education: $41.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,423.80 |
| Education | $41.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,148.45 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $961.31 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $703.33 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $579.11 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Celgene Corporation | $460.87 | 2022-2024 | Zeposia |
| Genzyme Corporation | $405.25 | 2022-2025 | |
| Intercept Pharmaceuticals, INC. | $195.71 | 2022-2025 | Ocaliva |
| Lilly USA, LLC | $183.03 | 2024-2025 | Omvoh |
| Pfizer INC. | $159.52 | 2019-2025 | |
| Qol Medical, LLC | $155.11 | 2019-2025 | Sucraid, Sucraid |
| Merck Sharp & Dohme LLC | $111.48 | 2020-2024 | Dificid |
| Madrigal Pharmaceuticals | $101.78 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $101.33 | 2022-2025 | Dupixent |
| Ferring Pharmaceuticals INC. | $100.15 | 2019-2025 | Rebyota, Clenpiq |
| Amgen INC. | $90.51 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celltrion USA INC. | $86.06 | 2024 | Vegzelma, Zymfentra |
| Novo Nordisk INC | $78.29 | 2025 | Wegovy |
| Vivus LLC | $68.89 | 2024-2025 | Qsymia, Pancreaze |
| Evoke Pharma, INC. | $64.37 | 2021-2025 | |
| Alfasigma USA, INC. | $58.10 | 2020 | |
| Redhill Biopharma INC. | $43.09 | 2020-2023 | Talicia, Movantik, Aemcolo |
| Covidien LP | $39.59 | 2019 | |
| Daiichi Sankyo INC. | $35.93 | 2022 | |
| Biocon Biologics INC | $34.65 | 2025 | Hulio |
| Eisai INC. | $30.30 | 2025 | |
| Baxter Healthcare | $29.33 | 2022 | |
| Ironwood Pharmaceuticals, INC | $24.75 | 2024 | |
| Fresenius Kabi USA, LLC | $23.72 | 2023 | Idacio |
| Exact Sciences Corporation | $21.91 | 2025 | Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $19.87 | 2025 | Voquezna |
| Organon LLC | $18.37 | 2022 | |
| Braintree Laboratories, INC. | $16.50 | 2025 | Suflave, Sutab |
| Boston Scientific Corporation | $15.25 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.22 | 2020 | |
| Biomerieux INC | $9.92 | 2019 | |
| Micro-Tech Endoscopy USA, INC. | $6.76 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Janki Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.